Secretable human platelet-derived factor V originates from the plasma pool.
Factor Va (FVa), derived from plasma or released from stimulated platelets, is the essential protein cofactor of the prothrombinase complex. Plasma-derived factor V (FV) is synthesized by the liver, whereas the source of the platelet-derived cofactor has not been unambiguously identified. Megakaryocytes, platelet precursors, are known to synthesize platelet proteins and to endocytose proteins from plasma (ie, fibrinogen) and then package these proteins into alpha-granules. To determine which mechanism accounts for FV presence in platelets, two patients heterozygous for FVLeiden who underwent allogeneic transplantation from homozygous FV wild-type donors (bone marrow [BM] or liver) were studied. Patient JMW, whose skin biopsy specimen showed heterozygous FVLeiden, received a BM transplant from a wild-type homozygous FV donor as analyzed from posttransplant peripheral blood cells. Patient FW, whose native liver is heterozygous for FVLeiden, received a homozygous wild-type FV liver. Because each individual has two distinct genetic pools of factor V in liver and megakaryocytes, it was possible to determine whether secretable platelet-derived FV was normal or contained the FVLeiden mutation. Platelet-derived FVa released from thrombin-activated platelets from a normal individual, an individual heterozygous for the FVLeiden mutation, and the two patients was incubated with phospholipid vesicles and activated protein C (APC). Western blotting analyses using a monoclonal antibody that allows distinction between platelet-derived FVa and FVaLeiden subsequent to APC-catalyzed cleavage were then performed. Based on the accumulation of proteolytic fragments derived from APC-induced cleavage, analyses of platelet-derived FVa from JMW demonstrated both normal FVa and FVaLeiden consistent with a plasma-derived origin of the secretable platelet-derived FVa. Western blotting analyses of the APC-cleaved platelet-derived FVa from FW showed a wild-type phenotype, despite the presence of a FVLeiden allele in her megakaryocyte genome, also consistent with a plasma origin of her secretable platelet-derived FVa. Platelets do not appear to endocytose the plasma cofactor, because a 35-hour incubation of platelet-rich plasma with 125I-factor V showed no specific association/uptake of the radiolabeled ligand with the platelet pellet. Collectively, these results show for the first time that the majority of secretable platelet-derived factor V is endocytosed by megakaryocytes from plasma and is not exclusively synthesized by these cells, as previously believed.
Camire
R M
RM
Department of Biochemistry, University of Vermont, College of Medicine, Burlington; the Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Pollak
E S
ES
Kaushansky
K
K
Tracy
P B
PB
D000208:Acute Disease; D000328:Adult; D001792:Blood Platelets / Q000378:metabolism*; D016026:Bone Marrow Transplantation; D006502:Budd-Chiari Syndrome / Q000601:surgery; D002678:Chimera; D003594:Cytoplasmic Granules / Q000378:metabolism; D004247:DNA / Q000235:genetics; D004705:Endocytosis; D005165:Factor V / Q000378:metabolism*; D015943:Factor Va / Q000378:metabolism; D005260:Female; D006579:Heterozygote; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy; D008099:Liver / Q000378:metabolism; D016031:Liver Transplantation; D008533:Megakaryocytes / Q000378:metabolism*; D008875:Middle Aged; D010949:Plasma / Q000378:metabolism*; D011486:Protein C / Q000378:metabolism; D014184:Transplantation, Homologous
D011486:Protein C; C095381:factor V Leiden; D015943:Factor Va; D005165:Factor V; D004247:DNA